SCHEMBL5092345

SCHEMBL5092345

CCCc1c(O)cc(OC)cc1CC(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.60
▸ KDM4E B2RXH2 2/20 0.60
▸ ABL1 P00519 1/20 0.60
▸ MAPT P10636 1/20 0.60
▸ RECQL P46063 1/20 0.60
▸ RIN1 Q13671 1/20 0.60
▸ CTDSP1 Q9GZU7 1/20 0.60
▸ HSD17B10 Q99714 1/20 0.49
▸ PTGES O14684 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ HMGCR P04035 2/20 0.42
▸ PTPN1 P18031 3/20 0.41
▸ PTPN11 Q06124 2/20 0.41
▸ PTPN2 P17706 1/20 0.41
▸ CYP3A4 P08684 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ CAMK2A Q9UQM7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5089943 0.87 KDM4E (0.44) POLBKDM4EABL1MAPTRECQL
SCHEMBL4405608 0.76 POLB (0.65) POLBKDM4EABL1MAPTRECQL
SCHEMBL509824 0.75 HSD17B10 (0.54) POLBKDM4EABL1MAPTRECQL
SCHEMBL5093626 0.74 MTNR1A (0.49) HSD17B10TDP1L3MBTL1MTNR1AMTNR1B
SCHEMBL7115040 0.74 HMGCR (0.50) HMGCRPTPN1CYP3A4
SCHEMBL30335932 0.74 POLB (0.73) POLBKDM4EABL1MAPTRECQL
SCHEMBL3296862 0.74 POLB (0.73) POLBKDM4EABL1MAPTRECQL
SCHEMBL12477951 0.72 POLB (0.59) POLBKDM4EABL1MAPTRECQL
SCHEMBL6035932 0.72 HSD17B10 (0.70) POLBKDM4EABL1MAPTRECQL
SCHEMBL28355178 0.71 HMGCR (0.60) POLBKDM4EABL1MAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348017-B2 Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin SHISEIDO CO., LTD. (JP) 2008-03-25 — — US disclosed
EP-1422224-B1 DITHIAZOLE COMPOUNDS, MATRIX METALLOPROTEASE INHIBITORS AND EXTERNAL PREPARATIONS FOR THE SKIN SHISEIDO CO LTD (JP) 2007-12-19 — — EP disclosed
US-20040236111-A1 Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin SHISEIDO CO., LTD. (JP) 2004-11-25 — — US disclosed
EP-1422224-A1 DITHIAZOLE COMPOUNDS, MATRIX METALLOPROTEASE INHIBITORS AND EXTERNAL PREPARATIONS FOR THE SKIN Shiseido Co., Ltd. (JP) 2004-05-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236111-A1 Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin MMP1, MMP2, MMP3 POLB 1019/4885KDM4E 1020/4885ABL1 4227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback